Overview

• Entrada Therapeutics Q3 net loss widens to $44.1 mln from $14.0 mln last year

• Collaboration revenue drops to $1.6 mln from $19.6 mln due to plan completion

• Company extends cash runway into Q3 2027 with $327 mln in cash and securities

Outlook

• Entrada expects to report ELEVATE-44-201 data in Q2 2026

• Company plans to report ELEVATE-45-201 data in mid-2026

• Company's cash runway extended into Q3 2027

Result Drivers

• DMD PROGRAM COSTS - Increased R&D expenses driven by costs related to DMD programs and higher personnel expenses

• COLLABORATION REVENUE DECLINE - Revenue drop attributed to completion of collaboration with Vertex

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Entrada Therapeutics Inc is $18.50, about 62.5% above its November 5 closing price of $6.94

Press Release: ID:nGNX3s0t0P

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)